MELBOURNE, Australia, April 08, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce an innovative partnership between GTG, and Humanise Health launching a "Know Your Risk" event featuring the company's unique Risk Assessment portfolio, to be held at The Langham, Pasadena, California on the 21st of May. This unique gathering is dedicated to empowering women by ...

MELBOURNE, Australia, April 02, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to report the company's new digital strategy, led by the company's recently appointed strategic advisor, Dr. Malcolm Bohm, is having a significant positive impact across all facets of GTG's social media platforms. The various analytical markers all showed uplifts, in some cases there was ...

MELBOURNE, Australia, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, "Company", "GTG"))), is pleased to announce the launch of a wide-reaching customer – targeted digital advertising campaign in the United States. This comprehensive program will drive Consumer Initiated Testing (CIT) for the company's geneType Risk Assessment Tests. The campaign will commence end of March 2024 and will scale up throughout the remainder of the year. The U.S. wellness testing market is projected ...

[Annual Results for the year ended June 30, 2023](index=1&type=section&id=Annual%20Results%20for%20the%20year%20ended%20June%2030%2C%202023) This report details Genetic Technologies' financial performance, strategic advancements, leadership updates, and future outlook for the fiscal year ended June 30, 2023 [Financial and Commercial Overview](index=1&type=section&id=Financial%20and%20Commercial%20Overview) Genetic Technologies reported a **28% revenue increase to A$8.686 million** for FY2023, driven by its successful transition to a commercial entity with three core brands Revenue Performance | Metric | Value | Change vs. 2022 | | :--- | :--- | :--- | | Revenue | A$8.686 million | +A$1.891 million (+28%) | - The company has transformed from an R&D organization to one with significant revenues anchored in three brands: geneType, EasyDNA, and AffinityDNA[4](index=4&type=chunk) - Commercial growth is being driven by both the Business to Business (B2B) channel (geneType) and the Direct to Consumer (DTC) channel (EasyDNA and Affinity DNA brands)[3](index=3&type=chunk) [Strategic Growth and Innovation](index=1&type=section&id=Strategic%20Growth%20and%20Innovation) The company is expanding its network, forming a strategic alliance with QIAGEN, and advancing its product pipeline, including a comprehensive breast and ovarian cancer risk test and an expanded Multi-Test Panel - Twenty medical practices in the US and Australia are now routinely referring patients for geneType testing, with the network expanding weekly[5](index=5&type=chunk) - A strategic alliance with QIAGEN is being formed to establish a "Centre of Excellence" in Australasia, aimed at enhancing automation, increasing capacity, and driving commercial opportunities for geneType[11](index=11&type=chunk) - Developed the world's first Comprehensive Breast & Ovarian Cancer Risk Test, which uses a simple saliva sample[7](index=7&type=chunk) - The geneType Multi-Test Panel was expanded to include melanoma, pancreatic cancer, and atrial fibrillation, now offering risk assessments for **nine diseases** covering up to **70% of annual mortalities**[9](index=9&type=chunk) - The science team has successfully published **seven peer-reviewed manuscripts**, providing evidence for the efficacy of the geneType test[8](index=8&type=chunk) [Leadership and Future Outlook](index=2&type=section&id=Leadership%20and%20Future%20Outlook) GTG has strengthened its U.S. medical leadership by appointing Dr. Joel Evans and continues to gain endorsements from Key Opinion Leaders, aiming for profitability within the next 18 months - Appointed Dr. Joel Evans in the U.S., a leader in clinical and functional medicine, to reinforce the company's commitment to advancing healthcare[12](index=12&type=chunk) - The company is collaborating with and receiving endorsements from Key Opinion Leaders (KOLs) such as Dr. Carolyn Young, Dr. William Stanford, and Dr. Lisa Larkin, which is helping to expand its reach into new medical practices[13](index=13&type=chunk) - After transitioning to a revenue-earning organization over the last 18 months, the company is now on a determined journey towards attaining profitability in the **next 18 months**[15](index=15&type=chunk) [About Genetic Technologies & Forward-Looking Statements](index=3&type=section&id=About%20Genetic%20Technologies%20%26%20Forward-Looking%20Statements) This section provides a corporate overview of Genetic Technologies as a global leader in genomics-based testing and includes a standard legal disclaimer regarding forward-looking statements and associated risks - Genetic Technologies is a global leader in genomics-based tests for health, wellness, and serious diseases, offering a comprehensive portfolio including Carrier screening, NIPT, and advanced predictive testing with its proprietary Polygenic Risk Scores (PRS) platform[18](index=18&type=chunk) - The announcement contains forward-looking statements that are subject to risks and uncertainties, and the company does not undertake any obligation to publicly update them except as required by law[19](index=19&type=chunk)

Commission file number 000-51504 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EX- CHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SEC ...

Genetic Technologies Limited (NASDAQ:GENE) Q1 2023 Earnings Conference Call November 3, 2022 8:00 PM ET Company Participants Adrian Mulcahy - Investor Relations Simon Morriss - Chief Executive Officer Adrian Mulcahy [Starts Abruptly] Genetic Technologies First Quarter FY '23 Investor Webinar. We have with us today, which is great news, is Simon Morriss, the CEO of Genetic Technologies. And the way we're going to run this is, Simon is going to go through some prepared slides, he's going to talk through some ...

Commission file number 000-51504 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTI ...

Genetic Technologies Limited (NASDAQ:GENE) Q3 2022 Earnings Conference Call April 20, 2022 6:00 PM ET Company Participants Simon Morriss – Chief Executive Officer Mike Tonroe – Chief Financial Officer Dr. George Muchnik – Non-Executive Director and Medical Advisor Conference Call Participants MichaelTonroe Hello and welcome to our Quarter Three business update. I'm Mike Tonroe, Chief Financial Officer Genetic Technologies. I'm also your house and moderator. Thank you for taking the time to join us today. Th ...

Exhibit 99.41 HALF YEAR REPORT Genetic Technologies Limited Appendix 4D Half-year ended 31 December 2021 Name of entity: Genetic Technologies Limited ABN: 17 009 212 328 Half-year ended: 31 December 2021 Previous period: 31 December 2020 Results for announcement to the market | | | | | $ | | --- | --- | --- | --- | --- | | Revenue for ordinary activities | Up | 12,379% | to | 2,051,016 | | Net loss after tax (from ordinary activities) for the period | | | | | | attributable to members | Up | (11.7)% | to | ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR (Address of principal executive offices) Simon Morriss, Chief Executive O ...